Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-day randomized blinded dose-ranging study of topical E6201 gel in psoriasis vulgaris
2009-014815-11Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of e6201 in plaque psoriasis (8 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Jan 2010; status: completed.
02
Drugs
e6201
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2009-014815-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014815-11.